The DOI matches its Crossref record.
Anti-Cancer Drug Design
Open accessAbstract
The recent elucidation of some of the critical molecular events involved in the maintenance of the neoplastic phenotype has engendered a new realism in cancer research. Not only is there a more unified conceptual base for such hitherto disparate disciplines as cytogenetics, chemical carcinogenesis and viral oncology but the new information suggests novel and in many respects, more rational approaches to treatment. These developments are to be welcomed, not least because they will ultimately make the costly and inefficient screening procedures on which advances in cancer chemotherapy have so largely relied, less empirical and more objective. The appearance this month of a new quarterly journal Anti Cancer Drug Design (published by the Macmillan Press Ltd) is therefore desirable and timely. Its aims and scope which are complementary to those of the British Journal of Cancer provide for a multidisciplinary, but coherent forum for the publication of papers in cell and molecular biology, biophysics, molecular pharmacology and medicinal chemistry which identify a rational basis for therapeutic intervention. There are many potential cellular 'targets' of chemotherapy ranging from tumour cell DNA itself to critical enzyme pathways, oncogene products, and cell-surface associated antigens to mention but a few. Some of these themes are represented in the first issue: Polarographic analysis of calfthymus DNA shows that Platinum compounds with anti-tumour activity induce conformational changes which are different from those induced by Pt compounds with no anti-tumour effect; the potent biological activity of azaspiranes can be effected by compounds of this class other than those containing germanium, and include cytotoxic as well as potentially immunostimulatory effects; the bistriazenes, a novel type of triazene derivative, act as prodrugs for the cytotoxic monomethyltriazenes; the antitumour activity of actinomycin D analogues results in part from their ability to form reactive reduced oxygen species; ESR techniques may be used to study molecular events relevant to the lower general toxicity and cumulative cardiotoxicity of 4'epidoxorubicin than the widely clinically used doxorubicin, and antibody-targetted drug (methotrexate) carrier conjugates appear to involve a lysosomotropic mechanism of action rather than extracellular cleavage of the drug from its carrier. It is anticipated that future contributions, both theoretical and applied, will exploit new principles of structure-activity relationships and disclose new methods of visualising three-dimensional structures of drugs in relation to their receptors. Hopefully this approach will identify agents with selectivity for the products encoded by oncogenes. These proteins, which are essential to malignant behaviour provide ideal targets for chemotherapy because interference with them should arrest tumour growth. Supported by the Cancer Research Campaign and with an interdisciplinary Editorial Board of international standing, Anti Cancer Drug Design is a useful addition to the cancer chemotherapy literature in particular and to the oncology literature in general.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Crystal structure of the Src family tyrosine kinase Hck
Sicheri, F., Moarefi, I., & Kuriyan, J. (1997) · Nature · doi:10.1038/385602a0 · Cited by 1,172
Tubulin as a target for anticancer drugs: Agents which interact with the mitotic spindle
Jordan, A., Hadfield, J. A., Lawrence, N. J., & McGown, A. T. (1998) · Medicinal Research Reviews · doi:10.1002/(sici)1098-1128(199807)18:4<259::aid-med3>3.0.co;2-u · Cited by 673
Zvelebil, M. J., Barton, G. J., Taylor, W. R., & Sternberg, M. J. E. (1987) · Journal of Molecular Biology · doi:10.1016/0022-2836(87)90501-8 · Cited by 435
Polyamines: from Molecular Biology to Clinical Applications
Jänne, J., Alhonen, L., & Leinonen, P. (1991) · Annals of Medicine · doi:10.3109/07853899109148056 · Cited by 340
Fernandez, P. M., Tabbara, S. O., Jacobs, L. K., Manning, F. C. R., Tsangaris, T. N., Schwartz, A. M., Kennedy, K. A., & Patierno, S. R. (2000) · Breast Cancer Research and Treatment · doi:10.1023/a:1006332011207 · Cited by 338
Universal strategies in research and drug discovery based on protein-fragment complementation assays
Michnick, S. W., Ear, P. H., Manderson, E. N., Remy, I., & Stefan, E. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2311 · Cited by 319
Charge‐Reversal Drug Conjugate for Targeted Cancer Cell Nuclear Drug Delivery
Zhou, Z., Shen, Y., Tang, J., Fan, M., Van Kirk, E. A., Murdoch, W. J., & Radosz, M. (2009) · Advanced Functional Materials · doi:10.1002/adfm.200900825 · Cited by 311
Myc Recruits P-TEFb to Mediate the Final Step in the Transcriptional Activation of the cad Promoter
Eberhardy, S. R., & Farnham, P. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m207441200 · Cited by 262
Metadata
- Authors
- Moore, M.
- Venue
- British Journal of Cancer
- Published
- 1985-11-01
- Volume
- 52
- Issue
- 5
- Pages
- i3-i3
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W1984099824
- Cited by
- 397
- References
- 0
- FWCI
- 7.15
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.